METTL3 and esophageal squamous cell carcinoma: In this study, the potential of elvitegravir, an United States Food and Drug Administration‐approved drug for the treatment of human immunodeficiency virus (HIV) infection, targeting METTL3 in ESCC was highlighted [60].